麻豆传媒

Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance

A quarter patients with high-risk, BCG-unresponsive disease were recurrence free at 3 years

Results from interim analysis suggest "potential to disrupt the NMIBC treatment landscape"

Investigational intravesical solution led to complete response rate of 79%

Barriers exist in identifying risk, but strategies are available

Older patients will have different care goals, preferences, geriatric oncologist says

Overprescribing a continuing problem, Benjamin Davies tells urologists

Approach in small ongoing trial resulted in reduction in tumor size and complexity

But patients with BCG-refractory disease may be better suited for cystectomy

In phase III trial, 53% achieved complete response at 3 months

Past data support "biological plausibility" for link, says researcher

Findings question earlier retrospective data that pointed to possible survival benefit

Superior outcomes observed versus approach where chemo follows newer agents